
SINCE 2019
QBOID
Chief Technology Officer
CTO, Qboid · Computer Vision · University of Padova
Palo Alto, California
He makes computer vision measure the physical world, fast enough to run on a phone.
Francesco Peruch is CTO of Qboid, where he owns the depth-camera station (US 12,620,113) that detects a parcel, segments it, and computes its dimensions on its own. He came up through Aquifi, co-inventing the thin structured-light optics that Google, Apple and Meta later cited 80 times, after a Padova PhD in computer vision for medical imaging. His signature is older than any of it: MEDS, a skin-lesion segmenter he built to run in a fraction of a second and validated against expert dermatologists.

SINCE 2019
Chief Technology Officer
EVERYTHING ELSE · 4 WORKS
The whole record, newest first – tap any moment and Aster tells the story.
As CTO of Qboid since 2019, Francesco owns the depth-camera dimensioning station he had been building toward for a decade. Its granted patent, US 12,620,113, detects a parcel on a working surface, segments it by depth, computes its dimensions, and quietly self-recalibrates between scans — the measurement instinct from his medical-imaging doctorate, now a shipping product he directs.
At Aquifi, Francesco rose from software engineer to Principal Software Architect for Computer Vision, working both sides of the sensor. He co-invented the thin structured-light optics — a 2.33 mm dual-function-DOE illuminator (US 9,503,708) and the single-DOE despeckling projector (US 9,826,216) later cited 80 times — then turned the depth cameras toward measurement: volumetric sizing, timing-constrained factory scanning, and perspective-corrected label reading.
“1% to 5% (or more) of the optical energy... is concentrated in the zero-order spot, and the zero-order spot may be 100 to 500 times brighter than any other portion of the pattern.”
A continuous bachelor-through-doctorate run in Information Engineering at the University of Padova, framed by a PhD in computer vision for medical imaging. There Francesco first-authored MEDS (IEEE TBME, 2014), a melanocytic-lesion segmenter that runs in a fraction of a second on a cell phone and tracks expert dermatologists more closely than a moderately-experienced one does — the instinct behind everything that followed.
“very experienced dermatologists disagree with its segmentations less than they disagree with the segmentations of state-of-the-art techniques, and in fact less than they disagree with the segmentations of dermatologists of moderate experience.”